Another BioTech Triumph

The past few months have demonstrated that mRNA vaccines can be highly effective, economically viable, and rapidly developed. It’s easy to imagine future applications where mRNA vaccines will become the standard approach and displace traditional technologies. 


At the heart of these successes lies advances in drug delivery, which may continue to provide momentum for not only the expanding repertoire of mRNA therapeutics, but a broad array of gene editing technologies (like CRISPR) as well. The exciting news last week from Intellia Therapeutics, is no exception.